Episode 6: The Talent That Got Away

The Coefficient Bio acquisition reveals the true price of computational biology talent at the frontier. Roughly $44 million per person, paid not for revenue or product but for scarce expertise that would otherwise take years to build internally. This is not anything Indian pharma payrolls can compete with, and trying to compete on that basis is a strategic error. The realistic Indian pharma AI strategy is not to out-bid Anthropic, Google, and OpenAI for individual computational biologists but to behave more like Eli Lilly did with Insilico Medicine - pay for access to an AI-native platform’s output, rather than trying to own the scarce talent that built the platform.• The Coefficient Bio deal anatomy: 8 months old, fewer than 10 people, $400 million, all-stock, and why that price was rational for the buyer• Where this talent actually comes from: Genentech’s 2025 layoffs as Roche pivoted toward embedded AI, releasing exactly the computational biology talent pool that Coefficient Bio’s founders came from• The acqui-hire versus platform-partnership distinction, using Eli Lilly’s contrasting $2.75 billion Insilico Medicine deal as the comparison case• What this means concretely for Indian pharma: the talent-acquisition path is largely foreclosed; the platform-partnership path remains genuinely open• The regulatory vacuum around AI-generated claims in pharma promotion and prescribing support, and the specific compliance exposure this creates for any Indian company moving fast on AI-assisted commercial toolsListen in to Episode 6 covering Wave 5 of the Bio-Health Supercycle. “My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com